DE69535234D1 - Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin - Google Patents

Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin

Info

Publication number: DE69535234D1
Authority: DE; Germany
Prior art keywords: allergic rhinitis; descarboethoxyloratadin; treatment; diseases containing; dcl
Prior art date: 1994-12-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69535234T

Other languages

English (en)

Other versions

DE69535234T2 (de

Inventor

A K Gunnar Aberg

John R Mccullough

Emil R Smith

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sunovion Pharmaceuticals Inc

Original Assignee

Sepracor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-30

Filing date

1995-12-11

Publication date

2006-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23443929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69535234(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-12-11 Application filed by Sepracor Inc filed Critical Sepracor Inc

2006-11-02 Publication of DE69535234D1 publication Critical patent/DE69535234D1/de

2007-09-13 Application granted granted Critical

2007-09-13 Publication of DE69535234T2 publication Critical patent/DE69535234T2/de

2015-12-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Virology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE69535234T 1994-12-30 1995-12-11 Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin Expired - Lifetime DE69535234T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US366651		1989-06-15
US08/366,651 US5595997A (en)	1994-12-30	1994-12-30	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
PCT/US1995/015995 WO1996020708A1 (en)	1994-12-30	1995-12-11	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Publications (2)

Publication Number	Publication Date
DE69535234D1 true DE69535234D1 (de)	2006-11-02
DE69535234T2 DE69535234T2 (de)	2007-09-13

Family

ID=23443929

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69535234T Expired - Lifetime DE69535234T2 (de)	1994-12-30	1995-12-11	Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
DE0799037T Pending DE799037T1 (de)	1994-12-30	1995-12-11	Verfahren und mittel zur behandlung der allergischen rhinitis und anderer erkrankungen mittels descarboethoxyloratadin

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE0799037T Pending DE799037T1 (de)	1994-12-30	1995-12-11	Verfahren und mittel zur behandlung der allergischen rhinitis und anderer erkrankungen mittels descarboethoxyloratadin

Country Status (21)

Country	Link
US (2)	US5595997A (de)
EP (3)	EP1078633A3 (de)
JP (1)	JP4237822B2 (de)
KR (1)	KR100442675B1 (de)
CN (2)	CN1267098C (de)
AT (1)	ATE339956T1 (de)
AU (1)	AU707541B2 (de)
BR (1)	BR9510129A (de)
CA (1)	CA2208836C (de)
CZ (1)	CZ293068B6 (de)
DE (2)	DE69535234T2 (de)
DK (1)	DK0799037T3 (de)
ES (1)	ES2144980T3 (de)
FI (1)	FI972781L (de)
HU (1)	HU229871B1 (de)
MX (1)	MX9704793A (de)
NO (3)	NO317555B1 (de)
NZ (1)	NZ300398A (de)
PT (1)	PT799037E (de)
SK (3)	SK284834B6 (de)
WO (1)	WO1996020708A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI955979L (fi) *	1993-06-14	1995-12-13	Janssen Pharmaceutica Nv	Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US7211582B1 (en) *	1994-12-30	2007-05-01	Sepracor Inc.	Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) *	1994-12-30	2007-05-08	Sepracor Inc.	Compositions of descarboethoxyloratadine
CA2245162A1 (en) *	1996-02-08	1997-08-14	Merck & Co., Inc.	Method of treatment and pharmaceutical composition
SK54599A3 (en) *	1996-10-31	2000-08-14	Schering Corp	Composition for the treatment of asthma, containing loratadine and a decongestant
US6308328B1 (en)	1997-01-17	2001-10-23	Scientific-Atlanta, Inc.	Usage statistics collection for a cable data delivery system
PE71699A1 (es) *	1997-02-07	1999-08-03	Sepracor Inc	Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
AU776837B2 (en) *	1997-02-07	2004-09-23	Sunovion Pharmaceuticals Inc.	Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
US5900421A (en) *	1997-02-11	1999-05-04	Sepracor Inc.	Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) *	1997-02-28	1999-08-17	Sepracor Inc.	Methods for treating urinary incontinence using descarboethoxyloratadine
SK286103B6 (sk) *	1997-12-23	2008-03-05	Schering Corporation	Farmaceutický prostriedok na liečenie respiračných a kožných ochorení s obsahom aspoň jedného antagonistu leukotriénu a aspoň jedného antihistaminikaa jeho použitie
US6140337A (en) *	1997-12-23	2000-10-31	Schering Corporation	Methods for the treatment of mental disorders
DE69919789T2 (de) *	1998-06-30	2005-09-08	Pfizer Products Inc., Groton	Loratadin zur Verwendung als Antiarrhythmikum
PT1380297E (pt) *	1998-07-10	2009-07-06	Schering Corp	Composições orais de 8-cloro-6,11-di-hidro-11-(4- piperidilideno)-5h-benzo[5,6]ciclo-hepta[1,2-b]piridina
PA8481801A1 (es) *	1998-09-10	2000-09-29	Schering Corp	Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
WO2000057880A1 (en) *	1999-03-29	2000-10-05	Schering Corporation	Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
US6100274A (en) *	1999-07-07	2000-08-08	Schering Corporation	8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
AR025711A1 (es) *	1999-09-21	2002-12-11	Schering Corp	El uso de la desloratadina para la preparacion de un medicamento para tratar y prevenir estados alergicos e inflamatorios
PE20010752A1 (es) *	1999-09-22	2001-07-17	Schering Corp	Uso de desloratadina para el tratamiento de estados alergicos e inflamatorios
ES2284531T3 (es) *	1999-10-08	2007-11-16	Schering Corporation	Tratamiento nasal topico usando desloratadina y furoato de mometasona.
US6114346A (en) *	1999-10-22	2000-09-05	Schering Corporation	Treating sleep disorders using desloratadine
SK287105B6 (sk)	1999-12-20	2009-12-07	Schering Corporation	Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
SK287684B6 (sk)	1999-12-20	2011-06-06	Schering Corporation	Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
MXPA02006347A (es) *	1999-12-21	2002-12-13	Schering Aktiengesllschft	Tratamiento decondiciones alergicas e inflamatorias.
US7405223B2 (en) *	2000-02-03	2008-07-29	Schering Corporation	Treating allergic and inflammatory conditions
WO2001056571A1 (en) *	2000-02-03	2001-08-09	Schering Corporation	Treating allergic and inflammatory conditions
EP1267870A2 (de) *	2000-04-07	2003-01-02	Schering Corporation	Hemmung der zytokinbildung
WO2002036124A2 (en) *	2000-10-30	2002-05-10	Schering Corporation	Treatment and method using loratadine and montelukast
AU2002256967A1 (en) *	2000-10-30	2002-09-12	Schering Corporation	Treating or reducing the risk of cardiovascular disease
WO2002036077A2 (en) *	2000-11-06	2002-05-10	Andrx Pharmaceuticals, Inc.	Once a day antihistamine and decongestant formulation
US6599914B2 (en) *	2001-04-24	2003-07-29	Schering Corporation	Inhibition of cytokine generation
US20030236275A1 (en) *	2002-06-20	2003-12-25	Schering Corporation	Treatment methods of nasal congestion and nasal obstruction
US6720002B2 (en) *	2001-07-20	2004-04-13	R.P. Scherer Technologies, Inc.	Antihistamine formulations for soft capsule dosage forms
US20040258741A1 (en) *	2001-10-17	2004-12-23	Takaaki Terahara	Percutaneous absorption preparations
US6863901B2 (en)	2001-11-30	2005-03-08	Collegium Pharmaceutical, Inc.	Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
MXPA04005417A (es) *	2001-12-05	2004-10-11	Alcon Inc	Uso de antagonista de h1 y un esteroide seguro para el tratamiento de la rinitis.
US6827946B2 (en) *	2001-12-05	2004-12-07	Collegium Pharmaceutical, Inc.	Compositions containing both sedative and non-sedative antihistamines
US20030004179A1 (en) *	2002-05-21	2003-01-02	Affrime Melton B	Treating allergic and inflammatory conditions
US6962924B2 (en) *	2002-08-05	2005-11-08	Sandoz Ag	Salt and polymorphs of desloratadine hemifumarate
DE60217934T2 (de) *	2002-09-24	2007-05-24	Morepen Laboratories Ltd.	Verfahren zur herstellung von desloratadin
US8092831B2 (en) *	2002-11-08	2012-01-10	Andrx Pharmaceuticals, Llc	Antihistamine and decongestant system
CZ200798A3 (cs) *	2004-07-07	2007-06-20	Egis Gyogyszergyár Nyrt.	Nový pseudopolymorf desloratadinu vytvorený s oxidem uhlicitým
WO2006008512A2 (en) *	2004-07-16	2006-01-26	Cipla Limited	Anti-histaminic composition
US20060154948A1 (en) *	2005-01-12	2006-07-13	Schering Corporation	Treating allergic and inflammatory conditions
CA2541045A1 (en) *	2006-03-24	2007-09-24	Pharmascience Inc.	A descarbonylethoxyloratadine containing pharmaceutical composition
NZ573173A (en)	2006-06-01	2012-03-30	Msd Consumer Care Inc	Phenylephrine pharmaceutical formulation and compositions for colonic absorption
EP2120945A1 (de) *	2007-02-28	2009-11-25	Collegium Pharmaceutical, Inc.	Antihistamin-kombination
US20090054338A1 (en) *	2007-08-06	2009-02-26	Aberg A K Gunnar	Synergisms between repartitioning and immunomodulating compounds
AU2008302190A1 (en) *	2007-09-18	2009-03-26	Stephen Wills	Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
US8073633B2 (en) *	2008-12-30	2011-12-06	The Invention Science Fund I, Llc	Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8321151B2 (en)	2008-12-30	2012-11-27	The Invention Science Fund I, Llc	Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8315815B2 (en)	2008-12-30	2012-11-20	The Invention Science Fund I, Llc	Computational methods and systems for suggesting modulators of CYP450 as treatment options
AU2010260177A1 (en)	2009-06-16	2011-12-15	Merck Sharp & Dohme Corp.	Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
ATE525064T1 (de)	2009-07-01	2011-10-15	Tiefenbacher Alfred E Gmbh & Co Kg	Pharmazeutische zusammensetzung mit desloratadin
CA2690490C (en)	2010-01-19	2012-06-26	Accucaps Industries Limited	Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10383894B2 (en) *	2010-03-17	2019-08-20	Lutran Industries, Inc.	Human medicinal treatment using salt of peroxymonosulfuric acid
US8778971B2 (en)	2012-10-23	2014-07-15	Bridge Pharma, Inc.	Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en)	2012-10-23	2013-10-15	Bridge Pharma, Inc.	Medicinal treatment of dermal diseases in dogs
US20140120121A1 (en)	2012-10-30	2014-05-01	Bridge Pharma, Inc.	Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en)	2012-10-30	2015-10-01	Bridge Pharma, Inc.	Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9345697B2 (en)	2013-08-06	2016-05-24	Bridge Pharma, Inc.	Methods of treatment of non-histaminic pruritus
US9138431B2 (en)	2013-08-06	2015-09-22	Bridge Pharma, Inc.	Methods of treatment of histamine H-4 receptor-related pruritus
US9439895B2 (en)	2013-08-06	2016-09-13	Bridge Pharma, Inc.	Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
IT201900012645A1 (it) *	2019-07-23	2021-01-23	Eros Zanotti	Una composizione farmaceutica per l'uso nel trattamento delle chinetosi

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4282233B1 (en)	1980-06-19	2000-09-05	Schering Corp	Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
AU570306B2 (en) *	1984-02-15	1988-03-10	Schering Corporation	8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
US4804666A (en) *	1985-08-14	1989-02-14	Schering Corporation	Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) *	1986-10-31	1992-02-18	Schering Corporation	Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5019591A (en) *	1989-02-17	1991-05-28	Pennsylvania Research Corporation	Method for treating retinopathy and other small vessel disorders associated with diabetes
IL98572A (en) *	1990-06-22	1995-07-31	Schering Corp	Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use
US5416091A (en) *	1990-12-18	1995-05-16	Burroughs Wellcome Co.	Agents for potentiating the effects of antitumor agents and combating multiple drug resistance

1994
- 1994-12-30 US US08/366,651 patent/US5595997A/en not_active Expired - Lifetime
1995
- 1995-12-11 ES ES95943722T patent/ES2144980T3/es not_active Expired - Lifetime
- 1995-12-11 SK SK888-97A patent/SK284834B6/sk not_active IP Right Cessation
- 1995-12-11 BR BR9510129A patent/BR9510129A/pt not_active Application Discontinuation
- 1995-12-11 NZ NZ300398A patent/NZ300398A/en not_active IP Right Cessation
- 1995-12-11 HU HU9701905A patent/HU229871B1/hu unknown
- 1995-12-11 DE DE69535234T patent/DE69535234T2/de not_active Expired - Lifetime
- 1995-12-11 SK SK61-2005A patent/SK286079B6/sk not_active IP Right Cessation
- 1995-12-11 EP EP00113351A patent/EP1078633A3/de not_active Ceased
- 1995-12-11 KR KR1019970704502A patent/KR100442675B1/ko not_active Expired - Lifetime
- 1995-12-11 DK DK95943722T patent/DK0799037T3/da active
- 1995-12-11 EP EP95943722A patent/EP0799037B1/de not_active Expired - Lifetime
- 1995-12-11 MX MX9704793A patent/MX9704793A/es unknown
- 1995-12-11 CZ CZ19972026A patent/CZ293068B6/cs not_active IP Right Cessation
- 1995-12-11 DE DE0799037T patent/DE799037T1/de active Pending
- 1995-12-11 WO PCT/US1995/015995 patent/WO1996020708A1/en not_active Ceased
- 1995-12-11 CN CNB95197713XA patent/CN1267098C/zh not_active Expired - Lifetime
- 1995-12-11 JP JP52100296A patent/JP4237822B2/ja not_active Expired - Lifetime
- 1995-12-11 PT PT95943722T patent/PT799037E/pt unknown
- 1995-12-11 AT AT95943722T patent/ATE339956T1/de active
- 1995-12-11 CA CA002208836A patent/CA2208836C/en not_active Expired - Lifetime
- 1995-12-11 CN CN2006100878238A patent/CN1935141B/zh not_active Expired - Lifetime
- 1995-12-11 FI FI972781A patent/FI972781L/fi not_active Application Discontinuation
- 1995-12-11 SK SK50010-2007A patent/SK287257B6/sk not_active IP Right Cessation
- 1995-12-11 EP EP06100220A patent/EP1712232A1/de not_active Ceased
- 1995-12-11 AU AU45126/96A patent/AU707541B2/en not_active Expired
1997
- 1997-01-13 US US08/783,393 patent/US5731319A/en not_active Expired - Lifetime
- 1997-06-27 NO NO19973023A patent/NO317555B1/no not_active IP Right Cessation
2002
- 2002-01-15 NO NO20020211A patent/NO330421B1/no not_active IP Right Cessation
2011
- 2011-01-18 NO NO20110077A patent/NO20110077L/no active IP Right Review Request

Also Published As

Publication number	Publication date
NO317555B1 (no)	2004-11-15
JPH10512240A (ja)	1998-11-24
AU707541B2 (en)	1999-07-15
MX9704793A (es)	1997-10-31
ATE339956T1 (de)	2006-10-15
SK88897A3 (en)	1998-02-04
EP1712232A1 (de)	2006-10-18
ES2144980T3 (es)	2007-03-16
FI972781A0 (fi)	1997-06-27
CZ293068B6 (cs)	2004-02-18
EP1078633A2 (de)	2001-02-28
DE799037T1 (de)	2000-10-05
FI972781A7 (fi)	1997-08-27
FI972781L (fi)	1997-08-27
SK287257B6 (sk)	2010-05-07
EP1078633A3 (de)	2001-03-07
CA2208836A1 (en)	1996-07-11
WO1996020708A1 (en)	1996-07-11
SK286079B6 (sk)	2008-03-05
PT799037E (pt)	2006-12-29
NO20020211L (no)	1997-08-19
NO20020211D0 (no)	2002-01-15
CA2208836C (en)	2001-12-04
CZ202697A3 (cs)	1998-03-18
ES2144980T1 (es)	2000-07-01
NO20110077L (no)	1997-08-19
AU4512696A (en)	1996-07-24
US5731319A (en)	1998-03-24
JP4237822B2 (ja)	2009-03-11
DE69535234T2 (de)	2007-09-13
HU229871B1 (en)	2014-11-28
NO973023L (no)	1997-08-19
US5595997A (en)	1997-01-21
CN1935141A (zh)	2007-03-28
DK0799037T3 (da)	2007-02-12
EP0799037A1 (de)	1997-10-08
KR100442675B1 (ko)	2004-10-14
NO330421B1 (no)	2011-04-11
HK1008185A1 (en)	1999-05-07
BR9510129A (pt)	1997-12-30
CN1935141B (zh)	2013-04-24
SK284834B6 (sk)	2005-12-01
CN1176598A (zh)	1998-03-18
HUT77315A (hu)	1998-03-30
EP0799037B1 (de)	2006-09-20
EP0799037A4 (de)	1998-05-06
CN1267098C (zh)	2006-08-02
NO973023D0 (no)	1997-06-27
NZ300398A (en)	2001-04-27

Publication	Publication Date	Title
DE69535234D1 (de)	2006-11-02	Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
DE69636085D1 (de)	2006-06-08	Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE184792T1 (de)	1999-10-15	2-bromomelatonin zur behandlung von schlafstörungen
ATE204178T1 (de)	2001-09-15	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
JP2002532432A5 (de)	2006-12-21
ATE213411T1 (de)	2002-03-15	Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE4394931T1 (de)	1995-07-20	Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE137965T1 (de)	1996-06-15	Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69428325D1 (de)	2001-10-25	Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
DE60115432D1 (de)	2006-01-05	Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE69111974D1 (de)	1995-09-14	Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
DE69623316D1 (de)	2002-10-02	Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
NO893256L (no)	1990-02-16	Fremgangsmaate for fremstilling av furyltiazolderivater.
DE69307702D1 (de)	1997-03-06	Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
SE9903985D0 (sv)	1999-11-03	Use of nitric oxide
HU911272D0 (en)	1991-10-28	Process for the production of medical preparations containing hexetidine
DE69800906D1 (de)	2001-07-19	Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO961180L (no)	1996-03-22	Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
NO881798D0 (no)	1988-04-25	Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.

Legal Events

Date	Code	Title	Description
2007-10-18	8364	No opposition during term of opposition